Surface detection method for large active reflector antennas based on even-odd phase expansion
Sign Up to like & getrecommendations! Published in 2020 at "Optics and Lasers in Engineering"
DOI: 10.1016/j.optlaseng.2020.106249
Abstract: Abstract Surface distortion reduces the astronomical observation efficiency of large radio telescopes. Based on even-odd phase expansion, we present a semi-analytical phase retrieval algorithm for antennas equipped with an active surface system to detect its… read more here.
Keywords: based even; phase; even odd; surface ... See more keywords
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3726
Abstract: Abstract Purpose: This study investigated the efficacy and tolerability of cabozantinib plus nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma (mUC) that progressed on checkpoint inhibition (CPI). Patients and Methods: A phase I expansion cohort… read more here.
Keywords: metastatic urothelial; phase expansion; cabozantinib plus; urothelial carcinoma ... See more keywords
Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.3549
Abstract: 3549Background: XMT-1536 is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, broadly expressed in NSCLC and ovarian cancer. XMT-1536 utilizes the Dolaflexin p... read more here.
Keywords: adc; xmt 1536; ovarian cancer; phase expansion ... See more keywords
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5037
Abstract: 5037Background: Previous treatment with ICI is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for mUC. There is lack of data regarding the u... read more here.
Keywords: cabozantinib plus; plus nivolumab; nivolumab cabonivo; study cabozantinib ... See more keywords